Dimitry S.A. Nuyten

Dr. Nuyten is a physician-scientist with broad experience built over 15 years across all phases of drug development. He joined Arcus in August 2022 from Chief Medical Officer roles at Nektar Therapeutics and Aduro Biotech. Until 2019, he was Vice President and Immuno-Oncology Development Leader at Pfizer, responsible for the full development program and registrational strategy for Bavencio® and the development of multiple immuno-oncology programs. Earlier in his career, he led early development for immuno-oncology at Pfizer and served as Group Medical Director at Bristol-Myers Squibb in the early development oncology group. Dr. Nuyten received his M.D. from the University of Groningen and his Ph.D. from the University of Amsterdam. He trained as a radiation oncologist at the Netherlands Cancer Institute in Amsterdam and was a visiting scientist at Stanford University from 2004-2005.